Document is current
Any future updates will be listed below
-
Authors
,
Gelernter, Joel https://orcid.org/0000-0002-4067-1859
Sun, Ning
Polimanti, Renato
Pietrzak, Robert.
Levey, Daniel F.
Bryois, Julien https://orcid.org/0000-0002-4747-2166
Lu, Qiongshi https://orcid.org/0000-0002-4514-0969
Hu, Yiming
Li, Boyang https://orcid.org/0000-0003-2808-9986
Radhakrishnan, Krishnan
Aslan, Mihaela
Cheung, Kei-Hoi
Li, Yuli
Rajeevan, Nallakkandi https://orcid.org/0000-0002-2045-0872
Sayward, Frederick
Harrington, Kelly
Chen, Quan
Cho, Kelly
Pyarajan, Saiju
Sullivan, Patrick F. https://orcid.org/0000-0002-6619-873X
Quaden, Rachel
Shi, Yunling
Hunter-Zinck, Haley
Gaziano, J. Michael
Concato, John
Zhao, Hongyu https://orcid.org/0000-0003-1195-9607
Stein, Murray B. https://orcid.org/0000-0001-9564-2871
- License Information
-
More Information
Article History
Received: 27 September 2018
Accepted: 11 June 2019
First Online: 29 July 2019
Competing interests
: J.G. is named as a co-inventor on PCT patent application no. 15/878,640 entitled: “Genotype-guided dosing of opioid agonists,” filed 24 January 2018. M.B.S. has in the past 3 years been a consultant for Actelion, Aptinyx, Bionomics, Dart Neuroscience, Healthcare Management Technologies, Janssen, Jazz Pharmaceuticals, Neurocrine Biosciences, Oxeia Biopharmaceuticals, Pfizer, and Resilience Therapeutics. M.B.S. owns founders shares and stock options in Resilience Therapeutics and has stock options in Oxeia Biopharmaceuticals.
